Unlock instant, AI-driven research and patent intelligence for your innovation.

Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity

A compound and solvate technology, applied in the field of medicinal chemistry, can solve problems such as low selectivity and poor curative effect

Inactive Publication Date: 2017-05-24
TSINGHUA UNIV
View PDF4 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In recent years, the US FAD has successively approved multiple ALK inhibitors, such as crizotinib, ceritinib, etc., as well as the third-generation EGFR inhibitors currently in the late clinical stage, such as AZD9219, CO1686, etc., but currently There are still problems such as poor curative effect or low selectivity of similar drugs, so it is urgent to discover and find a class of new therapeutic drugs with high mutation resistance selectivity or multi-target inhibitory activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
  • Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
  • Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0169] Intermediate 11 (25mg, 0.10mmol) and Intermediate 20 (35mg, 0.12mmol) were dissolved in iPrOH (1mL), concentrated hydrochloric acid (24mg, 0.25mmol) was added, microwave reaction (250w, 130°C, 120min, 300psi) . Cool to room temperature, add EA (20mL), wash with saturated sodium bicarbonate (aq) (20mL×3), wash with saturated brine (20mL×3), column chromatography (D / M / Et 3 N=10:1:0.02), to obtain Example 1: 48 mg of off-white solid with a yield of 71%.

[0170] The structure verification data is as follows: 1 H NMR (CDCl 3 )δ (ppm): 10.01 (s, 1H), 8.46 (dd, J 1 =8.4Hz,J 2 =4.4Hz,1H),8.35(s,1H),7.47(t,J=7.6Hz,1H),7.23-7.15(m,2H),7.02-6.98(m,1H),6.45(d,J= 8.8Hz, 1H), 6.35(s, 1H), 5.87(s, 1H), 4.60(t, J=8.8Hz, 2H), 3.40(d, J=12.0Hz, 2H), 3.20(t, J= 8.8Hz, 2H), 2.67(t, J=12.0Hz, 2H), 2.33(s, 6H), 2.29-2.23(m, 1H), 1.93(d, J=12.0Hz, 2H), 1.80(s, 3H),1.74(s,3H),1.68-1.58(m,2H).HRMS(ESI):m / z,calcd for C 27 h 36 N 6 o 2 P[M+H + ]:507.2637, found 507.2646.

Embodiment 2

[0172]Using Intermediate 11 (50 mg, 0.19 mmol) and Intermediate 21 (71 mg, 0.24 mmol) as raw materials, the same method as Example 1 was used to synthesize Example 2: 84 mg of off-white solid with a yield of 84%.

[0173] The structure verification data is as follows: 1 H NMR (DMSO-d 6 )δ (ppm): 11.51 (s, 1H), 8.66 (m, 1H), 8.24 (s, 1H), 8.02 (d, J = 3.2Hz, 1H), 7.54 (dd, J 1 =13.6Hz,J 2 =7.6Hz, 1H), 7.32(t, J=7.6Hz, 1H), 7.21(d, J=8.4Hz, 1H), 7.08(t, J=7.2Hz, 1H), 6.44(d, J=8.8 Hz,1H),4.49(t,J=8.4Hz,2H),3.41-3.39(m,2H),3.16(t,J=8.0Hz,2H),3.01(m,1H),2.64(t,J =12.0Hz,2H),2.53(s,6H),2.01(d,J=10.0Hz,2H),1.80(s,3H),1.77(s,3H),1.80-1.65(m,2H).HRMS (ESI): m / z, calcd for C 27 h 35 N 6 o 2 PF[M+H + ]:525.2543, found 525.2557.

Embodiment 3

[0175] Using Intermediate 11 (40 mg, 0.15 mmol) and Intermediate 22 (54 mg, 0.19 mmol) as raw materials, the same method as in Example 1 was used to synthesize Example 3: 35 mg of an off-white solid with a yield of 45%.

[0176] The structure verification data is as follows: 1 H NMR (DMSO-d 6 )δ(ppm):10.95(s,1H),8.51-8.50(m,1H),8.11(s,1H),7.95(d,J=5.6Hz,1H),7.52(d,J 1 =12.8Hz,J 2 =6.4Hz, 1H), 7.31(t, J=7.6Hz, 1H), 7.25(d, J=8.4Hz, 1H), 7.04(d, J=7.6Hz, 1H), 6.43(d, J=8.8 Hz,1H),5.96(d,J=5.6Hz,1H),4.49(t,J=8.4Hz,2H),3.39(m,2H),3.17-3.13(m,3H),2.63(t,J =12.0Hz,2H),2.43(s,6H),1.97-1.94(m,2H),1.78(s,3H),1.75(s,3H),1.62-1.59(m,2H).HRMS(ESI) :m / z, calcd for C 27 h 36 N 6 o 2 P[M+H + ]:507.2637, found 507.2634.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nitrogen-containing heterogeneous ring compound, a preparation method thereof and an application of the nitrogen-containing heterogeneous ring compound in inhibition of kinase activity. The general formula of the nitrogen-containing heterogeneous ring compound is represented as a formula I or a formula I', wherein R1, R2, R3 and R4 in the formula I or the formula I' are selected from any one of hydrogen, halogen, cyanogroup, hydroxyl, amidogen and substituted or unsubstituted C1-C6 alkyl groups independently, and a 3-10-membered ring system can be formed by any two groups in R1, R2, R3 and R4; M1, M2 and M3 are selected from CRa or N independently, and at least one of M1, M2 and M3 is N; W is selected from substituted or unsubstituted C1-C6 alkyl groups, substituted or unsubstituted C2-C6 alkenyl, unsubstituted or halogenated 4-8-membered alkine groups, substituted or unsubstituted C3-C8 naphthenic base, substituted or unsubstituted 4-8-membered heterocyclic groups, 5-10-membered aromatic or heteroaryl groups, substituted carbonyl, substituted sulfonyl and substituted or unsubstituted amidogen. The nitrogen-containing heterogeneous ring compound can inhibit EGFR (epidermal growth factor receptor) mutant kinase activity or ALK (anaplastic lymphoma kinase) activity and is a multi-target tumor therapeutic drug with a brand-new action mechanism.

Description

technical field [0001] The invention relates to a nitrogen-containing heterocyclic compound, a preparation method thereof and an application in inhibiting kinase activity, belonging to the technical field of medicinal chemistry. Background technique [0002] Molecular targeted therapy of tumors is based on the key proteins closely related to the occurrence and development of tumors, and selectively acts on signaling proteins by chemical means to kill tumor cells. The characteristics of targeted therapy are: high specificity, strong selectivity, and lower toxicity and side effects compared with traditional chemotherapy drugs; when used in combination, it can enhance the efficacy of traditional chemotherapy; targeted inhibitors are prone to drug resistance in clinical practice and make the therapeutic drugs invalidated. [0003] Lung cancer is the malignant tumor with the highest morbidity and mortality in the world, and the 5-year survival rate is only 16.8%. In 2010, the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07F9/6558C07F9/6561A61K31/675A61P35/00
CPCC07F9/53C07F9/6558C07F9/6561C07F9/65586
Inventor 汪舰别建波郎明
Owner TSINGHUA UNIV
PatSnap Eureka logo

PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.

X (Twitter)LinkedInYouTubeSubstack

© 2026 PatSnap. All rights reserved. 

Terms of Service

 | 

Privacy policy

 | 

Modern Slavery Act Transparency Statement